Skip to content

Frontlight ResearchEarly access

Institution

Tennessee Oncology

Nashville, United StatesWebsite

174running trials
114closed trials
3,456publications (OpenAlex)

Running trials

Recruiting
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07719361· Phase 1· Flare Therapeutics Inc.· Source
Recruiting
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
NCT07365319· Phase 2/3· Eikon Therapeutics· Source
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152· Phase 3· Immuneering Corporation· Source
Recruiting
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
NCT07629960· Phase 1/2· Blueprint Medicines Corporation· Source
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
NCT07422480· Phase 3· Takeda· Source
Recruiting
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
NCT06930755· Phase 1· Nerviano Medical Sciences· Source
Recruiting
Horizon Two: HR NDMM (MMRC-100)
NCT07053436· Phase 2· Multiple Myeloma Research Consortium· Source
Recruiting
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
NCT07469891· Phase 1· Prelude Therapeutics Incorporated· Source
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995· Phase 3· BioNTech SE· Source
Recruiting
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
NCT07544589· Phase 1· Dispatch Biotherapeutics· Source
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497· Phase 3· Bristol-Myers Squibb· Source
Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076· Phase 1/2· Bristol-Myers Squibb· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
NCT07421700· Phase 1/2· Pfizer· Source
Recruiting
A Study of BI 3810944 in Patients With Advanced Cancer
NCT07224425· Phase 1· Boehringer Ingelheim· Source
Recruiting
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT07284758· Phase 2· C4 Therapeutics, Inc.· Source
Recruiting
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT07227415· Phase 1/2· Pfizer· Source
Active, not recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07266441· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
NCT07287995· Phase 1/2· Astellas Pharma Global Development, Inc.· Source
Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338· Phase 1/2· Revolution Medicines, Inc.· Source
Recruiting
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
NCT07121946· Phase 1· LTZ Therapeutics, Inc.· Source
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Pfizer· Source
Recruiting
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
NCT07361562· Phase 1· Cogent Biosciences, Inc.· Source
Recruiting
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT07288359· Phase 1/2· Novartis Pharmaceuticals· Source
Recruiting
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
NCT07221474· Phase 2· Merck Sharp & Dohme LLC· Source
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· Phase 3· Eli Lilly and Company· Source
Recruiting
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
NCT07227402· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751· Phase 3· BioNTech SE· Source
Recruiting
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
NCT06745908· Phase 3· ImmunityBio, Inc.· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· Phase 3· Pfizer· Source
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· Phase 3· Pfizer· Source
Recruiting
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT07007312· Phase 3· Kura Oncology, Inc.· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· Phase 3· BeOne Medicines· Source
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521· Phase 3· Relay Therapeutics, Inc.· Source
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154· Phase 2· Astellas Pharma Global Development, Inc.· Source
Recruiting
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
NCT06931626· Phase 1· Nerviano Medical Sciences· Source
Recruiting
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT06991556· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872· Phase 3· BeOne Medicines· Source
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649· Phase 4· Eli Lilly and Company· Source
Recruiting
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
NCT06876662· Phase 4· Eli Lilly and Company· Source
Recruiting
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
NCT06926920· Phase 1/2· Gilead Sciences· Source
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06356571· Phase 2· Sanofi· Source
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354· Phase 3· Merck Sharp & Dohme LLC· Source

Showing 50 of 174.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lung cancer28 recruiting
Prostate cancer16 recruiting
Bladder cancer13 recruiting
Multiple myeloma13 recruiting
Triple-negative breast cancer11 recruiting
Kidney cancer10 recruiting
Colorectal cancer9 recruiting
Melanoma9 recruiting
Chronic lymphocytic leukaemia7 recruiting
Metastatic breast cancer7 recruiting
Ovarian cancer7 recruiting
Gastric and oesophageal cancer6 recruiting
Diffuse large B-cell lymphoma5 recruiting
Follicular lymphoma5 recruiting
Head and neck cancer5 recruiting
Pancreatic cancer5 recruiting
Cervical cancer4 recruiting
Endometrial cancer4 recruiting
Mantle cell lymphoma4 recruiting
Hodgkin lymphoma3 recruiting
Liver and biliary tract cancer3 recruiting
Myeloproliferative neoplasms3 recruiting
Childhood cancers2 recruiting
Mesothelioma2 recruiting
Sarcoma2 recruiting
Acute myeloid leukaemia1 recruiting
Brain metastases1 recruiting
Glioblastoma1 recruiting
Myelodysplastic syndromes1 recruiting
Neuroendocrine tumours1 recruiting

Closed trials

Withdrawn
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
NCT05948462· Phase 2· SCRI Development Innovations, LLC· Source
Terminated
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
NCT05908396· Phase 1· IGM Biosciences, Inc.· Source
Recruiting
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
NCT05780034· Phase 1· Accutar Biotechnology Inc· Source
Completed
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
NCT05759949· Phase 1· Relay Therapeutics, Inc.· Source
Terminated
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
NCT05514717· Phase 1· Day One Biopharmaceuticals, Inc.· Source
Terminated
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
NCT05631574· Phase 1· Biomea Fusion Inc.· Source
Completed
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
NCT05538572· Phase 1· Prelude Therapeutics Incorporated· Source
Completed
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
NCT05585034· Phase 1· Xencor, Inc.· Source
Terminated
Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies
NCT05537766· Phase 2· Kite, A Gilead Company· Source
Completed
Phase 2 Study of DKN-01 in Colorectal Cancer
NCT05480306· Phase 2· Leap Therapeutics, Inc.· Source
Terminated
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
NCT05267106· Phase 2· Incyte Corporation· Source
Withdrawn
To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer
NCT05212701· Phase 2· Dompé Farmaceutici S.p.A· Source
Terminated
Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma
NCT05359861· Phase 2· Coherus Oncology, Inc.· Source
Terminated
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NCT05252390· Phase 1· Nuvation Bio Inc.· Source
Terminated
Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
NCT05357898· Phase 1/2· SQZ Biotechnologies· Source
Terminated
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
NCT05121948· Phase 1· HiberCell, Inc.· Source
Completed
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
NCT05054725· Phase 2· Revolution Medicines, Inc.· Source
Completed
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
NCT05199337· Phase 1/2· K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.· Source
Terminated
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
NCT04984811· Phase 2· NeoImmuneTech· Source
Completed
FT576 in Subjects With Multiple Myeloma
NCT05182073· Phase 1· Fate Therapeutics· Source
Recruiting
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT04929223· Phase 1· Hoffmann-La Roche· Source
Completed
Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers
NCT05041257· Phase 2· AbbVie· Source
Completed
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
NCT04885998· Phase 1· Amgen· Source
Completed
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
NCT05039177· Phase 1/2· Erasca, Inc.· Source
Terminated
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
NCT04982926· Phase 1· Taiho Oncology, Inc.· Source
Completed
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
NCT04987203· Phase 3· AVEO Pharmaceuticals, Inc.· Source
Completed
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
NCT04956692· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
NCT04689828· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
NCT04872166· Phase 1· Edgewood Oncology Inc.· Source
Terminated
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
NCT04887831· Phase 2· G1 Therapeutics, Inc.· Source
Completed
XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer
NCT04825288· Phase 1/2· XBiotech, Inc.· Source
Terminated
Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
NCT04795713· Phase 1· Molecular Templates, Inc.· Source
Completed
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
NCT04752215· Phase 1· Boehringer Ingelheim· Source
Completed
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
NCT04799249· Phase 3· G1 Therapeutics, Inc.· Source
Completed
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
NCT04699630· Phase 2· SCRI Development Innovations, LLC· Source
Terminated
A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma
NCT04740034· Phase 1· Amgen· Source
Completed
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
NCT04774952· Phase 1· Revolution Medicines, Inc.· Source
Completed
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
NCT04744831· Phase 2· Daiichi Sankyo· Source
Completed
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
NCT04665843· Phase 2· Hoffmann-La Roche· Source
Recruiting
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04634552· Phase 2· Janssen Research & Development, LLC· Source
Completed
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
NCT04463771· Phase 2· Incyte Corporation· Source
Completed
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
NCT04488354· Phase 1· Calibr, a division of Scripps Research· Source
Terminated
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
NCT04543188· Phase 1· Pfizer· Source
Completed
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
NCT04620330· Phase 2· Verastem, Inc.· Source
Recruiting
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
NCT04683250· Phase 1/2· Taiho Pharmaceutical Co., Ltd.· Source
Completed
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
NCT03776071· Phase 3· Denovo Biopharma LLC· Source
Completed
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
NCT04666688· Phase 1/2· PureTech· Source
Completed
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
NCT04670679· Phase 1· Erasca, Inc.· Source
Completed
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT04619797· Phase 2/3· Hoffmann-La Roche· Source
Completed
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM
NCT04471844· NovoCure Ltd.· Source

Showing 50 of 114.

Registry name variants (69)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Tennessee Oncology
Nashville, Tennessee 37203
112 trials
Tennessee Oncology, PLLC
Nashville, Tennessee 37203
59 trials
Sarah Cannon Research Institute (Tennessee Oncology)
Nashville, Tennessee 37203
24 trials
Tennessee Oncology - Nashville
Nashville, Tennessee 37203
14 trials
Tennessee Oncology
Chattanooga, Tennessee 37404
8 trials
Sarah Cannon - Tennessee Oncology
Nashville, Tennessee 37203
7 trials
SCRI - Tennessee Oncology
Nashville, Tennessee 37203
7 trials
Tennessee Oncology, PLLC
Hermitage, Tennessee 37076
7 trials
Tennessee Oncology, PLLC - Investigational Drug Services
Nashville, Tennessee 37203
6 trials
Tennessee Oncology - Sarah Cannon Research Institute
Nashville, Tennessee 37203
6 trials
Tennessee Oncology, Pllc Nashville
Nashville, Tennessee 37203
5 trials
Sarah Cannon (Tennessee Oncology - Nashville)
Nashville, Tennessee 37203
4 trials
Tennessee Oncology, PLLC - Mount Juliet
Mount Juliet, Tennessee 37122
4 trials
The Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee 37203
4 trials
Tennessee Oncology, PLLC
Hendersonville, Tennessee 37075
3 trials
- NCT04579380Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
- NCT04539938A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
- NCT04585815Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Tennessee Oncology, PLLC-Elliston Place Plaza Medical Oncology &Hematology
Nashville, Tennessee 37203
3 trials
- NCT07421700Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- NCT07227415Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- NCT07222566Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Tennessee Oncology, PLLC - Saint Thomas West
Nashville, Tennessee 37205
3 trials
- NCT07421700Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- NCT07227415Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- NCT07222566Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Tennessee Oncology/SCRI
Nashville, Tennessee 37203
3 trials
- NCT05908396Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
- NCT04799249Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
- NCT03781063Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
SCRI - Tennessee Oncology - Nashville - Centennial
Nashville, Tennessee 37203-1625
2 trials
- NCT03776071A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
- NCT02716116A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
Tennessee Oncology, PLLC,2004 Hayes Street
Nashville, Tennessee 37203
2 trials
- NCT05382286Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
- NCT05382299Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Tennessee Oncology, PLLC,3443 Dickerson Road
Nashville, Tennessee 37207
2 trials
- NCT05382286Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
- NCT05382299Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Tennessee Oncology, PLLC,353 New Shackle Island Road
Hendersonville, Tennessee 37075
2 trials
- NCT05382286Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
- NCT05382299Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Tennessee Oncology, PLLC,397 Wallace Road
Nashville, Tennessee 37211
2 trials
- NCT05382286Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
- NCT05382299Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Tennessee Oncology, PLLC,4220 Harding Rd
Nashville, Tennessee 37205
2 trials
- NCT05382286Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
- NCT05382299Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Tennessee Oncology, PLLC,5653 First Blvd.
Hermitage, Tennessee 37076
2 trials
- NCT05382286Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
- NCT05382299Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology (Site 9000)
Nashville, Tennessee 37203
2 trials
- NCT07221474A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
  Contact: Study Coordinator
- NCT07227402A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
  Contact: Study Coordinator
Tennessee Oncology, PLLC - Greco-Hainsworth Centers for Research
Nashville, Tennessee 37203
2 trials
- NCT06727565Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
- NCT06413498A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Tennessee Oncology, PLLC - Hendersonville
Hendersonville, Tennessee 37075
2 trials
- NCT07421700Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- NCT07227415Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Tennessee Oncology, PLLC - Nashville Saint Thomas West
Nashville, Tennessee 37205
2 trials
- NCT07144280A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- NCT07028853This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Tennessee Oncology, PLLC,SCRI Oncology Partners
Nashville, Tennessee 37203
2 trials
- NCT05382286Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
- NCT05382299Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Tennessee Oncology, PLLC- Skyline
Nashville, Tennessee 37207
2 trials
- NCT07421700Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- NCT07227415Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Tennessee Oncology, PLLC- Southern Hills
Nashville, Tennessee 37211
2 trials
- NCT07421700Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- NCT07227415Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Duplicate_SCRI - Tennessee Oncology /ID# 269921
Nashville, Tennessee 37203-1632
1 trial
- NCT05041257Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers
One Oncology - Tennessee Oncology (Site 0098)
Nashville, Tennessee 37203
1 trial
- NCT06393374Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
  Contact: Study Coordinator
One Oncology - Tennessee Oncology (Site 4019)
Nashville, Tennessee 37203
1 trial
- NCT06077760A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Sarah Cannon Research Institute - Tennessee Oncology, PLLC
Nashville, Tennessee 37203
1 trial
- NCT04774952Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Tennessee Oncology (0036)
Nashville, Tennessee 37203
1 trial
- NCT06074588Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Tennessee Oncology, Greco-Hainsworth Center for Research
Nashville, Tennessee 37203
1 trial
- NCT06369285A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
  Contact: Puma Biotechnology, Inc. Clinical Operations Senior Director
Tennessee Oncology Hendersonville
Hendersonville, Tennessee 37075
1 trial
- NCT07028853This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Tennessee Oncology - Midtown
Nashville, Tennessee 37203
1 trial
- NCT06524375A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
Tennessee Oncology Nashville /ID# 269029
Nashville, Tennessee 37203
1 trial
- NCT05527184First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
Tennessee Oncology - Nashville - Midtown Center for Blood Cancers
Nashville, Tennessee 37203
1 trial
- NCT06472245Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
  Contact: Caroline Chevalier, MSc, MPH
Tennessee Oncology Nashville (Site 0004)
Nashville, Tennessee 37203
1 trial
- NCT03179436Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
Tennessee Oncology Nashville- Site Number : 8400012
Nashville, Tennessee 37203
1 trial
- NCT06356571A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Tennessee Oncology, PLLC- Elliston Place Plaza
Nashville, Tennessee 37203
1 trial
- NCT07227415Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Tennessee Oncology, PLLC - Elliston Place Plaza DDU
Nashville, Tennessee 37203
1 trial
- NCT07224425A Study of BI 3810944 in Patients With Advanced Cancer
  Contact: Boehringer Ingelheim
Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology (Site 0031)
Nashville, Tennessee 37203
1 trial
- NCT06136559A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
  Contact: Study Coordinator
Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology (Site 0831)
Nashville, Tennessee 37203
1 trial
- NCT07419295A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
  Contact: Study Coordinator
Tennessee Oncology, PLLC /ID# 207175
Nashville, Tennessee 37203
1 trial
- NCT03639194A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer
Tennessee Oncology, PLLC /ID# 215326
Nashville, Tennessee 37203
1 trial
- NCT04189614An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
Tennessee Oncology, PLLC /ID# 246283
Nashville, Tennessee 37203
1 trial
- NCT05599984Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
Tennessee Oncology, PLLC-Nashville-52568
Nashville, Tennessee 37203
1 trial
- NCT04752215A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Center for Blood Cancers
Nashville, Tennessee 37203
1 trial
- NCT06152575MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Tennessee Oncology, PLLC - Nashville Elliston Place Plaza DDU
Nashville, Tennessee 37203
1 trial
- NCT06152575MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Medical Oncology & Hematology
Nashville, Tennessee 37203
1 trial
- NCT06152575MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Tennessee Oncology, PLLC - Nashville Skyline
Nashville, Tennessee 37207
1 trial
- NCT07028853This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Tennessee Oncology, PLLC - Nashville Southern Hills
Nashville, Tennessee 37211
1 trial
- NCT07028853This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Tennessee Oncology, PLLC (Site 0001)
Nashville, Tennessee 37203
1 trial
- NCT03634540A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
Tennessee Oncology, PLLC (Site 0020)
Nashville, Tennessee 37203
1 trial
- NCT03162536A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
Tennessee Oncology (Sarah Cannon)
Nashville, Tennessee 37203
1 trial
- NCT03901469A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer
Tennessee Oncology (Site 0018)
Nashville, Tennessee 37203
1 trial
- NCT06841354A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
  Contact: Study Coordinator
Tennessee Oncology (Site 0051)
Nashville, Tennessee 37203
1 trial
- NCT04956692Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
Tennessee Oncology (Site 0068)
Nashville, Tennessee 37203
1 trial
- NCT07060807A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
  Contact: Study Coordinator
Tennessee Oncology (Site 0111)
Nashville, Tennessee 37203
1 trial
- NCT06393374Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
  Contact: Study Coordinator
Tennessee Oncology Site Number : 8400006
Nashville, Tennessee 37203
1 trial
- NCT04270409Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Tennessee Oncology - Skyline Satellite
Nashville, Tennessee 37201
1 trial
- NCT03734029Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Tennessee Oncology - SOUTHERN HILLS - SCRI - PPDS
Nashville, Tennessee 37211
1 trial
- NCT03268954Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Tennessee Oncology - ST THOMAS WEST - SCRI - PPDS
Nashville, Tennessee 37205
1 trial
- NCT03268954Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Tennessee Oncology - SUMMIT - SCRI - PPDS
Hermitage, Tennessee 37076
1 trial
- NCT03268954Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

Conditions

Diseases this institution publishes on or runs trials for.

Mantle cell lymphoma5 works · 12 trials

Institution data: ROR 03754ky26 (CC0-1.0)Updated 14 Nov 2026

Report an error